Fingerprint
Dive into the research topics of 'Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically